Uses of granulocyte-macrophage colony-stimulating factor in vaccine development

Current Opinion in Hematology

Volumn 7, Issue 3, 2000, Pages 168-173

  Warren, Thomas L ^a   Weiner, George J ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN;

ADJUVANT THERAPY; CANCER; CELL ACTIVATION; DENDRITIC CELL; GENE THERAPY; GENETIC TRANSFECTION; HEMATOPOIESIS; IMMUNITY; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; INFECTION; PRIORITY JOURNAL; REVIEW; TUMOR CELL; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; GENE THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY, ACTIVE; VACCINES, DNA;

EID: 0034002814     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200005000-00007     Document Type: Review

References (56)

1. 1 Hemmila MR, Chang AE: Clinical implications of the new biology in the development of melanoma vaccines. J Surg Oncol 1999, 70:263-274.
2. 2 Metcalf D: The granulocyte-macrophage colony-stimulating factors. Science 1985, 229:16-22.
3. 3 Taglietti M: Vaccine adjuvancy: a new potential area of development for GM-CSF. Adv Exp Med Biol 1995, 378:565-569.
4. 4 Jones T, Stern A, Lin R: Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant. Eur J Clin Microbiol Infect Dis 1994, 13(Suppl 2):47-53.
5. 5 Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC: Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 1998, 161:3042-3049.
6. 6 Carlsson T, Struve J: Granulocyte-macrophage colony-stimulating factor given as an adjuvant to persons not responding to hepatitis B vaccine [letter]. Infection 1997, 25:129.
7. 7 Disis ML, Grabstein KH, Sleath PR, Cheever MA: Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999, 5:1289-1297. The introduction to the paper provides an excellent overview of the immunology of vaccination, with a focus on generating cell-mediated immunity. In addition, the findings of the paper illustrate how the structure of an antigen and the manner in which it is processed impact on nature of the immune response.
8. 8 Lehmann PV, Sercarz EE, Forsthuber T, Dayan CM, Gammon G: Determinant spreading and the dynamics of the autoimmune T-cell repertoire [comments]. Immunol Today 1993, 14:203-208.
9. 9 Elson CJ, Barker RN, Thompson SJ, Williams NA: Immunologically ignorant autoreactive T cells, epitope spreading and repertoire limitation. Immunol Today 1995, 16:71-76.
10. 10 Babai I, Samira S, Barenholz Y, Zakay-Rones Z, Kedar E: A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin /neuraminidase and IL-2 or GM-CSF: I: vaccine characterization and efficacy studies in mice. Vaccine 1999, 17:1223-1238. This reference demonstrates the importance of antigen presentation and how GM-CSF potentiates the response. Importantly, the strategy used in this paper to enhance the immune response to the flu vaccine may soon enter the clinical setting.
11. 11 Babai I, Samira S, Barenholz Y, Zakay-Rones Z, Kedar E: A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/ neuraminidase and IL-2 or GM-CSF. II.Induction of Th1 and Th2 responses in mice. Vaccine 1999, 17:1239-1250.
12. 12 Tao MH, Levy R: Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma [comments]. Nature 1993, 362:755-758.
13. 13 Tripathi PK, Qin H, Bhattacharya-Chatterjee M, Ceriani RL, Foon KA, Chatterjee SK: Construction and characterization of a chimeric fusion protein consisting of an anti-idiotype antibody mimicking a breast cancer-associated antigen and the cytokine GM-CSF. Hybridoma 1999, 18:193-202. This provides a review of fusion protein generation and evaluation.
14. 14 DeMatos P, Abdel-Wahab Z, Vervaert C, Hester D, Seiglr H: Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. J Surg Oncol 1998, 68:79-91.
15. 15 Masurier C, Pioche-Durieu C, Colombo BM, Lacave R, Lemoine FM, Klatzmann D, Guigon M: Immunophenotypical and functional heterogeneity of dendritic cells generated from murine bone marrow cultured with different cytokine combinations: implications for anti-tumoral cell therapy. Immunology 1999, 96:569-577.
16. 16 Tjandrawan T, Martin DM, Maeurer MJ, Castelli C, Lotze MT, Storkus WJ: Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro. J Immunother 1998, 21:149-157.
17. 17 Paglia P, Chiodoni C, Rodolfo M, Colombo MP: Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo [comments]. J Exp Med 1996, 183:317-322.
18. 18 Porgador A, Snyder D, Gilboa E: Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996, 156:2918-2926.
19. 19 Porgador A, Gilboa E: Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 1995, 182:255-260.
20. 20 Mayordomo JI, Zorina T, Storkus WJ, Zitovel L, Garcia-Prats MD, DeLeo AB, Lotze MT: Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 1997, 15:94-103.
21. 21 Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, et al.: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995, 1:1297-1302.
22. 22 Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD: Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity [comments]. J Exp Med 1996, 183:283-287.
23. 23 Shimizu J, Suda T, Yoshioka T, Kosugi A, Fujiwara H, Hamaoka T: Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells. J Immunol 1989, 142:1053-1059.
24. 24 Grabbe S, Bruvers S, Gallo RL, Knisely TL, Nazareno R, Granstein RD: Tumor antigen presentation by murine epidermal cells. J Immunol 1991, 146:3656-3661.
25. 25 Boczkowski D, Nair SK, Snyder D, Gilboa E: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996, 184:465-472.
26. 26 Pardoll DM: Paracrine cytokine adjuvants in cancer immunotherapy. Ann Rev Immunol 1995, 13:399-415.
27. 27 Simmons SJ, Tjoa BA, Rogers M, Elgamal A, Kenny GM, Ragde H, et al.: GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate 1999, 39:291-297. Although this trial produced negative results, it provides insight into the use of GM-CSF as an immune adjuvant and the use of dendritic cells in cancer immunotherapy.
28. 29 van Elsas A, Hurwitz AA, Allison JP: Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999, 190:355-366. This technical paper explores the role of CTLA-4 and CD28 in generation of tolerance. It provides an excellent overview of the immunology of T cell activation.
29. 30 Shtil AA, Turner JG, Durfee J, Dalton WS, Yu H: Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma celts: the role of cytotoxic T lymphocytes. Blood 1999, 93:1831-1837.
30. 31 Turner JG, Tan J, Crucian BE, Sullivan DM, Ballester OF, Dalton WS, et al.: Broadened clinical utility of gene gun-mediated, granulocyte-macrophage colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model. Hum Gene Ther 1998, 9:1121-1130.
31. 32 Soo Hoo W, Lundeen KA, Kohrumel JR, Pham NL, Brostoff SW, Bartholomew RM, et al.: Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model. J Immunol 1999, 162:7343-7349.
32. 33 Stripecke R, Skelton DC, Gruber T, Afar D, Pattengale PK, Witte ON, et al.: Immune response to Philadelphia chromosome-positive acute lymphoblastic leukemia induced by expression of CD80, interleukin 2, and granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 1998, 9:2049-2062.
33. 34 Fujii S, Hamada H, Fujimoto K, Shimomura T, Kawakita M: Activated dendritic cells from bone marrow cells of mice receiving cytokine-expressing tumor cells are associated with the enhanced survival of mice bearing syngeneic tumors. Blood 1999, 93:4328-4335. These researchers explored the role of GM-CSF and dendritic cells in the induction of an anti-tumor response. In this paper, they speculate that GM-CSF exerts its adjuvant effect by recruiting and activating dendritic cells that then generate an anti-tumor cell mediated response.
34. 35 Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, et al.: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A 1998, 95:13141-13146. After immunization, lesions in patients treated showed a dense infiltration of T cells, dendritic cells, and macrophages, and at least 80% tumor destruction in 11 of 16 patients. Such evidence of an active immune response in peripheral lesions in this disease is welcome and extremely exciting.
35. 36 Cao X, Zhang W, Wang J, Zhang M, Huang X, Hamada H, et al.: Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells. Immunology 1999, 97:616-625.
36. 37 Jaffee EM, Abrams R, Cameron J, Donehower R, Duerr M, Gossett J, et al.: A phase 1 clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Hum Gene Ther 1998, 9:1951-1971. This publication of a clinical trial protocol provides an excellent introduction and discussion of the history and rationale behind therapy with irradiated tumors that have been transfected with the GM-CSF gene.
37. 38 Borrello I, Sotomayor EM, Cooke S, Levitsky HI: A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther 1999, 10:1983-1991.
38. 39 Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, et al.: Heterologous protection against influenza by injection of DNA encoding a viral protein [see comments]. Science, 1993, 259:1745-1749.
39. 40 Wang B, Ugen KE, Srikantan V, Agadjanyan MG, Dang K, Refaeli Y, et al.: Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1993, 90:4156-4160.
40. 41 Coney L, Wang B, Ugen KE, Boyer J, McCallus D, Srikantan V, et al.: Facilitated DNA inoculation induces anti-HIV-1 immunity in vivo. Vaccine 1994, 12:1545-1550.
41. 42 Rock KL, Goldberg AL: Degradation of cell proteins and the generation of MHC class I-presented peptides. Ann Rev Immunol 1999, 17:739-779.
42. 43 Rock KL: A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 1996, 17:131-137.
43. 44 Lee SW, Cho JH, Sung YC: Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. J Virol 1998, 72:8430-8436.
44. 45 Cho JH, Lee SW, Sung YC: Enhanced cellular immunity to hepatitis C virus nonstructural proteins by codelivery of granulocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization. Vaccine 1999, 17:1136-1144.
45. 46 Lee AH, Suh YS, Sung YC: DNA inoculations with HIV-1 recombinant genomes that express cytokine genes enhance HIV-1 specific immune responses. Vaccine 1999, 17:473-479.
46. 47 Rodriguez D, Rodriguez JR, Llorente M, Vazquez I, Lucas P, Esteban M, et al.: A human immunodeficiency virus type 1 Env-granulocyte-macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine. J Gen Virol 1999, 80(Pt 1):217-223.
47. 48 Sin JI, Kim JJ, Ugen KE, Ciccarelli RB, Higgins TJ, Weiner DB: Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-stimulating factor expression cassettes. Eur J Immunol 1998, 28:3530-3540.
48. 49 Weiss WR, Ishii KJ, Hedstrom RC, Sedegah M, Ichino M, Barnhart K, et al.: A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J Immunol 1998, 161:2325-2332. This report provides an excellent example of the technical approaches needed to create a DNA vaccine.
49. 50 Stevenson FK, Zhu D, King CA, Ashworth LJ, Kumar S, Hawkins RE: Idiotypic DNA vaccines against B-cell lymphoma. Immunol Rev 1995, 145:211-228.
50. 51 Syrengelas AD, Chen TT, Levy R: DNA immunization induces protective immunity against B-cell lymphoma. Nature Med 1996, 2:1038-1041.
51. 52 King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, Thompsett AR, et al.: DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma [comments]. Nat Med 1998, 4:1281-1286.
52. 53 Hakim I, Levy S, Levy R: A nine-amino acid peptide from IL-1β augments antitumor immune responses induced by protein and DNA vaccines. J Immunol 1996, 157:5503-5511.
53. 54 Syrengelas AD, Levy R: DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J Immunol 1999, 162:4790-4795. One of the founders of the field of cancer immunotherapy explores in depth the mechanism of the immune response to DNA vaccination.
54. 55 Nawrath M, Pavlovic J, Dummet R, Schultz J, Strack B, Heinrich J, et al.: Reduced melanoma tumor formation in mice immunized with DNA expressing the melanoma-specific antigen gp100/pmel17. Leukemia 1999, 13(Suppl1):48-51.
55. 56 Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al.: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-549.
56. 57 Liu HM, Newbrough SE, Bhatia SK, Dahle CE, Krieg AM, Weiner GJ: Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood 1998, 92:3730-3736.